SABSW · As filed with the SEC
SAB Biotherapeutics income statement, by quarter
The statement as SAB Biotherapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) · USD, except per-share amounts
| USD, except per-share amounts | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q4 2024† 3 months ended Dec 31, 2024 |
|---|---|---|---|---|---|---|
| Total revenue | — | — | — | — | — | 114,698† |
| Research and development | 16,172,000 | 13,397,977 | — | 8,970,010 | 6,996,660 | — |
| General and administrative | 7,205,000 | 6,599,759 | — | 3,708,959 | 2,735,401 | — |
| Total operating expenses | 23,377,000 | 19,997,736 | — | 12,678,969 | 9,732,061 | — |
| Loss from operations | (23,377,000) | (19,997,736) | — | (12,678,969) | (9,732,061) | — |
| Changes in fair value of warrant liabilities | (1,111,000) | (482,474) | — | 61,598,908 | (627,056) | — |
| Interest expense | (62,000) | (62,745) | — | (43,292) | (64,345) | — |
| Interest income | 1,709,000 | 1,047,197 | — | 655,233 | 13,562 | — |
| Other income, net | 350,000 | 626,873 | — | 765,881 | 295,630 | — |
| Warrant Issuance Cost | — | — | — | (4,852,292) | — | — |
| Total other income (expense) | 886,000 | 1,128,851 | — | 58,124,438 | (382,209) | — |
| Net loss | (22,491,000) | (18,868,885) | — | 45,445,469 | (10,114,270) | — |
| Other comprehensive income (loss): | ||||||
| Unrealized loss, change in fair value of available-for-sale securities, net of reclassification adjustment and tax | — | (546,791) | — | 87,751 | 328 | — |
| Unrealized loss, change in fair value of available-for-sale securities | (717,000) | — | — | — | — | — |
| Reclassification adjustment for gain on sale of available-for-sale securities included in net income | 0 | — | — | — | — | — |
| Foreign currency translation gain | 10,000 | 137,517 | — | (723) | 95,460 | — |
| Total comprehensive loss | (23,198,000) | (19,278,159) | — | 45,532,497 | (10,018,482) | — |
| Loss per common share attributable to the Company's shareholders | ||||||
| Basic loss per common share | (0.28) | (0.35) | — | 0.50 | (1.09) | — |
| Diluted loss per common share | (0.28) | (0.35) | — | (0.21) | (1.09) | — |
| Weighted-average common shares outstanding - basic | 79,753,100 | 53,558,639 | — | 10,660,500 | 9,294,469 | — |
| Weighted-average common shares outstanding - diluted | 79,753,100 | 53,558,639 | — | 77,863,263 | 9,294,469 | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.